SG/CALL/BRISTOL-MYERS SQUIBB/60/0.1/20.12.24

SG/CALL/BRISTOL-MYERS SQUIBB/60/0.1/20.12.24 Share Price

DE000SV45489

Delayed Deutsche Boerse AG 09:52:03 03/06/2024 pm IST
0.022 ^EUR	+29.41%

1 month	-51.43%
3 months	-86.92%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/60/0.1/20.12.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	11:09pm	MT
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	07:44pm	BU
Bristol Myers: presents advances in lung cancer	06:28pm	CF
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	05:39pm	BU

More news

Quotes 5-day view

Date	Price	Change
03/24/03	0.022	+29.41%
31/24/31	0.017	+21.43%
30/24/30	0.014	-6.67%
29/24/29	0.015	0.00%
28/24/28	0.015	-11.76%

Delayed Quote Deutsche Boerse AG

Last update June 03, 2024 at 09:52 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SV4548
ISIN	DE000SV45489
Date issued	09/05/2023
Strike	60 $
Maturity	20/12/2024 (200 Days)
Parity	10 : 1
Emission price	1.25 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.31 €
Lowest since issue	0.013 €
Delta	0.07x
Omega	10.53
Premium	43.97x
Gearing	142.48x
Moneyness	0.6980
Difference Strike	18.2 $
Difference Strike %	+30.34%
Spread	0.01 €
Spread %	31.25%
Intrinsic value	0.000000

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus